Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen‐allergic patients
Allergy2015Vol. 70(7), pp. 795–804
Citations Over TimeTop 10% of 2015 papers
Emmanuel Nony, Julien Bouley, Maxime Le Mignon, P. Lemoine, K. Jain, S. Horiot, Laurent Mascarell, Marc Pallardy, Renaud Vincentelli, Patrizia Leone, A. Roussel, Thierry Batard, Kathy Abiteboul, Blaise Robin, Olivier Beaumont, Monica Arvidsson, S. Rak, Philippe Moingeon
Abstract
Recombinant Bet v 1 has been produced as a well-characterized pharmaceutical-grade biological drug. Sublingual administration of rBet v 1 tablets is safe and efficacious in patients with BP allergic rhinoconjunctivitis.
Related Papers
- → Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications(2001)60 cited
- → Sublingual and oral immunotherapy(2004)15 cited
- → Progress of sublingual immunotherapy in bronchial asthma and allergic rhinitis(2011)
- → Study of Efficacy of Sublingual Immunotherapy in Cases Asthma & Allergic Rhinitis in India(2017)
- Progress of sublingual immunotherapy in bronchial asthma and allergic rhinitis(2011)